Postoperative Pain Market to Rising Steadily at a 7.93% CAGR Owing to Growing Number of Surgeries, During the Study Period [2018-2030], Says DelveInsight
An increase in the number of surgeries, advancement in the current and emerging treatment options, and rise in the patient population proffer the impetus to Postoperative Pain Market Growth in the 7MM.
LAS VEGAS, June 30, 2021 /PRNewswire/ -- DelveInsight's "Postoperative Pain Market" report provides a thorough comprehension of the Postoperative Pain historical and forecasted epidemiology and the Postoperative Pain market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Postoperative Pain market report also proffers an analysis of the current Postoperative Pain treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Opioids, NSAIDs, and anesthetics mainly cover the current Postoperative Pain market. Current treatment for Postoperative Pain involves approved drugs such as Anjeso, Dextenza, Inveltys, and others in nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.
Some approved opioids medications are also present in the Postoperative Pain market, such as Dsuvia, approved in 2018 in both US and EU. Some other approved drugs that are being used in Postoperative Pain are Penthrox and Exparel.
Korsuva (CR845), Co-crystal E-58425 (Tramadol/Celecoxib), Zalviso (sufentanil), Tramadol IV, Zynrelef (bupivacaine and meloxicam), Posimir (Bupivacaine Solution), Olinvyk (oliceridine), Xaracoll (bupivacaine hydrochloride), and others are the pipeline candidates, which are expected to enter the Postoperative Pain Market in the forecast period (2021–2030).
The growth of the Postoperative Pain Market to boost due to investment in research picks up that increases the demand for better diagnosis and treatment options for the pain. Recently, drugs with novel mechanisms of action and combinations are being investigated to overcome the challenges of this entity. Many agents show promising activity in Postoperative Pain because of recent advances in the better understanding of the drug. Also, the market needs new therapy with superior efficacy as strong as opioids but fewer side effects and drug dependency. In addition, there has been raising awareness about multimodal analgesia among clinicians and patients to decrease the reliance on single-modal treatment.
Postoperative Pain market size might be hindered due to a lack of effective diagnosis. Also, pain assessment is not effectively implemented in many hospitals. Available pharmacological therapies are associated with decreased patient compliance and opioid substance use. Specific adverse effects may hamper the drug recommendations. Strict regulatory requirements for drug approval and high treatment costs are impediments to the Postoperative Pain market growth.
Several key pharmaceutical companies such as Menarini Group, Guidotti Farma, AcelRx Pharmaceuticals, Trevena, Inc., Heron Therapeutics, Innocoll Pharmaceuticals, DURECT Corporation, Pacira Pharmaceuticals, Baudax Bio, Bausch & Lomb, Ocular Therapeutix, Kala Pharmaceuticals, Inc, Medical Developments International Ltd (MVP), Hyloris Pharmaceuticals, AFT Pharmaceuticals, Cara Therapeutics, Vivozon, Avenue Therapeutics, Arthritis Innovation Corporation, MedinCell, Unither Pharmaceuticals, Esteve Pharmaceuticals, Formosa Pharmaceuticals, Neumentum Pharmaceuticals, Acadia Pharmaceuticals Inc., Nevakar, Inc., Taiwan Liposome Company (TLC), Viatris Inc. (formerly known as Mylan Inc.), Teikoku Pharma USA, Inc., Novartis Pharmaceuticals, Oculis, PainReform LTD, Concentric Analgesics, Mati Therapeutics Inc., and others are developing novel products to improve the Postoperative Pain treatment outlook.
Postoperative Pain is defined as a condition of tissue injury together with muscle spasms after surgery. Postoperative Pain patients can be sub-segmented based on severity as mild, moderate, and severe.
As per DelveInsight's estimates, the Postoperative Pain incident cases were around 66,426,881 cases in the 7MM in 2020. Moreover, the United States has the highest percentage of the Postoperative Pain patient pool among these countries.
Postoperative Pain management aims to decline pain intensity, increase patient comfort, and improve postoperative outcomes. Pain-relieving analgesics include opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and acetaminophen.
Opioids are a large group of pain-relieving drugs that are utilized for alleviating pain in postoperative cases. These drugs majorly comprise fentanyl, hydromorphone, morphine, oxycodone, oxymorphone, and tramadol. In addition, the approved opioids include Zalviso, Olinvyk (Olinvo), Dzuveo/Dsuvia, Nucynta, DepoDur, and others. However, opioids have many dose-limiting side effects that range from bothersome to life-threatening.
Recently, in February 2021, FDA approved Posimir, a potential drug that is awaiting launch. Similar to Posimir, bupivacaine is the active ingredient in Pacira Biosciences' Exparel, also indicated for postsurgical pain relief. Being the clear market leader in branded post-surgical local anesthesia, Exparel (bupivacaine liposome injectable suspension) has generated impressive sales after its approval (effectively from the US). Posimir has been approved with limited labels, and thus, it is slightly evident that it might not give a head-to-head competition to Exparel. In addition, Xaracoll is an implant that is a unique, non-injectable, drug-device combination in the form of a fully bioresorbable collagen implant containing bupivacaine hydrochloride, providing postsurgical pain relief through the delivery of bupivacaine, a local anesthetic, at the surgical site. Although it is presently approved in the US, weak efficacy data might prevent it from becoming a substantial competitor in the pain management market.
In 2018, local anesthetics grew around 20% in value, while opioids declined.Thus, it can be anticipated that local anesthetic demand will be very high in the Postoperative Pain market, and future, upcoming therapies can hold a tight market. Besides, the potential market for an effective long-acting local anesthetic working 72-h is enormous.
Although Posimir and Xaracoll might not be significant threats to Exparel's market leadership, Heron Therapeutics' Zynrelef is ripe to compete with Exparel. Formerly known as HTX-011, it is one such drug with 72 h anesthetic action that is initially targeting many million procedures, including hospital inpatient, hospital outpatient, and ambulatory surgical centers (ASCs). The drug could be a threat to Pacira Biosciences' Exparel as recently the HTX-011 received a nod from US FDA, and soon it will be launched in the US market.
While Zynrelef has received marketing approvals in the EU, Exparel has been in the Postoperative Pain market for more than a decade and has the edge over others. Despite that, Heron's candidate might stand out and become a direct competitor to Exparel in the future; several factors, including multiple advantages shown in its safety and efficacy data, might play a role. The drawbacks could be a limited use, which is only at the incision site and not in peripheral nerve blocks. HTX-011 has been tested in surgical settings and requires a surgeon to administer the drug, whereas Exparel has been adopted in expanding ASC settings. The popularity and use will depend on the product's cost after approval and availability all over. Nevertheless, HTX-011 approval has been full of controversy. Still, DelveInsight anticipates that it will cover a massive Postoperative Pain market by 2030.
HTX-011 will face stiff competition in the US and EU-5: DelveInsight's Analyst Views. In the US, HTX-011 will compete with Marcaine (bupivacaine hydrochloride injection, solution, marketed by Pfizer Inc.) and generic forms of bupivacaine; Naropin (ropivacaine, marketed by Fresenius Kabi USA, LLC) and its generic forms; Exparel (bupivacaine liposome injectable suspension, marketed by Pacira BioSciences, Inc.); Xaracoll (bupivacaine HCl implant, marketed by Innocoll Pharmaceuticals Limited); Posimir (marketed by Durect Corporation); Anjeso (meloxicam injection, marketed by Baudax Bio, Inc.); Ofirmev (acetaminophen injection, marketed by Mallinckrodt Pharmaceuticals) and generic forms of IV acetaminophen; and potentially other products in development for Postoperative Pain management that reach the US market. Similarly, in EU-5, numerous generic local anesthetics and other nonopioids for postoperative pain management are available in the EU, and other products in development for postoperative pain management may also reach the EU market. For example, in November 2020, the EC granted marketing authorization for Exparel (bupivacaine liposome injectable suspension, marketed by Pacira BioSciences, Inc. in the US) for postsurgical analgesia. Pacira BioSciences, Inc. has indicated that it expects launching Exparel in the EU in the second half of 2021.
If approved, Cara Therapeutics IV CR845 would be competing within the overall acute postoperative pain market. However, the company expects to compete primarily with injectable mu-opioid analgesics, such as morphine, fentanyl, and hydromorphone.
DelveInsight's Chronic Pain Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. The market players are Pfizer, Eli Lilly and Company, Regeneron, Teva Pharmaceuticals, Mitsubishi Tanabe Pharma Corporation, ABBVie, Stayble Therapeutics, Aptinyx, Lateral Pharma, Samumed, Sorrento Therapeutics, Ampio Pharmaceuticals, and others that are developing therapies for Chronic Pain patients.
DelveInsight's Acute Ocular Pain Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Key players involved in the Acute Ocular Pain pipeline are Ocular Therapeutix, Kala Pharmaceuticals, Sun Pharmaceutical, Bausch & Lomb, Formosa Pharmaceuticals, Aldeyra Therapeutics, Sylentis, and others.
"Oncolytic Virus Cancer Therapy" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. CG Oncology, Oncolytics Biotech, Astellas Pharma, DNAtrix, Nouscom, ImmVira Pharma, Targovax, Istari Oncology, SillaJen Biotherapeutics, and others are a few companies that will be drifting Oncolytic Virus Cancer Therapy treatment scenario.
Capnography Devices Market Insights, Competitive Landscape and Market Forecast-2026 report delivers an in-depth understanding of Capnography Devices and the historical and forecasted epidemiology. Some notable companies such as Smiths Medical, Dragerwerk AG & Co. KGaA., Welch Allyn, Inc., Masimo Corporation, Philips Healthcare, Medtronic, Inc., Nonin Medical, Nihon Kohden Corporation, and others are changing Capnography Devices Market dynamics.
Cardiac Resynchronization Therapy Market Insights, Competitive Landscape and Market Forecast-2026 report delivers an in-depth understanding of Cardiac Resynchronization Therapy. Boston Scientific Corporation, Medtronic, Medico S.p. A, Microport Scientific Corporation, Biotronik, EBR Systems, Inc, and Abbott are pulling up the Cardiac Resynchronization Therapy market.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also providesBusiness Consulting Serviceswith a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.